Latest Biotech News

Electra Therapeutics raised $350 million in an upsized IPO to advance precision immune therapies, according to the company’s financing update. The proceeds are earmarked to support development of...

Beacon Therapeutics reported that its gene therapy for X-linked retinitis pigmentosa (XLRP) succeeded in a pivotal trial, improving visual acuity and positioning the company to pursue regulatory...

Cue Biopharma said its chronic spontaneous urticaria program—an Xolair challenger candidate—hit a Phase 2 primary endpoint in a China study. The positive midstage outcome supports moving the drug...

Alkermes said its orexin agonist ALKS 7290 showed tolerability and an efficacy signal in a randomized Phase 1 trial in adults with ADHD. In the study, participants started with a median symptom...

Two biotech reverse mergers were announced within hours of each other, as companies explore alternative public-market routes while the IPO window shows signs of thawing in 2026. Lisata...

ADARx Pharmaceuticals filed to target about $319 million in a potential IPO, aiming to fund continued development of its siRNA program in Phase 3. The filing also positions the company in the...

Industry analysts say health systems are not fully prepared for the next wave of GLP-1-based care that extends beyond diabetes and obesity into broader cardiometabolic and liver indications. The...

Researchers reported that CLN8—mutated in Batten disease—acts as a stereospecific acyltransferase involved in producing a lysosomal lipid central to cellular recycling. The work published in...

A preclinical study highlighted a new approach to checkpoint therapy for cancers resistant to existing immune checkpoint inhibitor strategies. The work focuses on a dual T-cell activator concept...

Cue Biopharma reported that its chronic hives candidate cleared a Phase 2 study in China, achieving the trial’s primary endpoint in chronic spontaneous urticaria. The readout marks the company’s...

Beacon Therapeutics said its gene therapy for X-linked retinitis pigmentosa (XLRP) produced a successful pivotal trial outcome, setting up an FDA path for the rare vision-loss condition. The...

Telix agreed to acquire ITM Isotope Technologies Munich in a deal valued at about $1.65 billion upfront, according to the reported terms tied to its lead radiopharmaceutical development and an...

Lisata Therapeutics and North Immunology both announced stock-for-stock reverse mergers alongside private placements, landing new public-company vehicles focused on late-stage runway and clinical...

Electra Therapeutics launched an upsized initial public offering to raise $350 million, positioning the company around a first-in-class precision immunology drug candidate for a rare...

A new industry analysis argues that GLP-1 uptake is moving beyond proof of weight loss and into a broader evidence-and-delivery challenge for pharma, payers, and primary care. The piece highlights...

Eli Lilly presented early clinical data for brenipatide, its GIP/GLP-1 receptor agonist candidate, supporting once-weekly dosing selection for substance use, psychiatric, and immunologic...

Researchers identified a mobile-cell platform approach to track and map long-lived plasma cell behavior inside a human bone marrow-on-a-chip (BMOC) system, reported in Science Advances. The work...

i-SENS reported that its CareSens Air continuous glucose monitoring system met proposed European clinical accuracy standards in a pooled analysis published in Diabetes Therapy. The result makes...

A report examines how whole-patient support models are reshaping oncology care as treatments become more personalized and patient-managed outside of clinic visits. It points to the growing...

Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich after the radiopharma peer was hit by a surprise FDA rejection, according to the reported deal terms. The transaction values...